TB test firm completes second tranche of series D
This article was originally published in Clinica
Oxford Immunotec, a specialist in T cell measurement, has closed the second tranche of a $26m series D financing. The first tranche was completed in July 2009. The round was led by New Leaf Venture Partners, and included contributions from new investor Kaiser Permanente and existing shareholders. The financing will allow Oxford Immunotech to accelerate commercialisation of its flagship product, the T-SPOT.TB test. The lab-based cellular blood test is designed to diagnose tuberculosis and latent TB infection by measuring T cells that have been activated specifically by Mycobacterium tuberculosis antigens. It is currently marketed in the US, Europe, Canada and over 40 other countries worldwide. The funds will also be used to develop new diagnostic products from the UK company's platform T-SPOT technology.